Tenosynovial Giant Cell Tumor (TGCT)

Celleron Gains Worldwide Rights to Shelved Roche Drug

Agreements, Business, Cancer, Clinical Studies, Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), Licensing, Monoclonal Antibodies, Product Rights, Tenosynovial Giant Cell Tumor (TGCT), Therapeutics

U.K.-based Celleron Therapeutics signed a licensing agreement with Swiss pharma giant Roche for the worldwide rights to the cancer drug emactuzumab, a monoclonal antibody directed against colony-stimulating factor 1 (CSF-1R) expressed on macrophages.

August 12, 2020/by Andrew Humphreys

U.S. FDA approves Daiichi Sankyo’s treatment for rare joint tumor

Approvals, FDA, FDA/Regulatory, Joints, Limbs, Non-Cancerous Tumors, Oncology, Tenosynovial Giant Cell Tumor (TGCT)

The U.S. Food and Drug Administration approved Daiichi Sankyo Co. Ltd.’s Turalio for adult patients with a type of rare, non-cancerous tumor affecting joints and limbs.

August 2, 2019/by Reuters Health

With the books closed on another ASCO meeting, it’s clear to see that checkpoint inhibitors keep showing a promise.

June 5, 2019/by BioSpace

Daiichi Sankyo’s Tumor Drug Meets Primary Endpoint in Late-Stage Study

Anti-colony-stimulating factor 1 receptor (CSF1R) antibodies, Cancer Cells, Clinical Trials, Collaboration, CSF1R Inhibitors, Monoclonal Antibodies, R&D, Shares, Tenosynovial Giant Cell Tumor (TGCT)

Daiichi Sankyo announced that its Phase III ENLIVEN trial of pexidartinib met its primary endpoint.

October 31, 2017/by BioSpace